140.90
2.00 (1.44%)
| Penutupan Terdahulu | 138.90 |
| Buka | 139.50 |
| Jumlah Dagangan | 1,165,144 |
| Purata Dagangan (3B) | 1,743,790 |
| Modal Pasaran | 1,360,367,744 |
| Harga / Jualan (P/S) | 5.76 |
| Harga / Buku (P/B) | 2.30 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 2 Sep 2025 |
| Margin Keuntungan | -79.80% |
| Margin Operasi (TTM) | -75.99% |
| EPS Cair (TTM) | -0.160 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.84% |
| Nisbah Semasa (MRQ) | 4.66 |
| Aliran Tunai Operasi (OCF TTM) | -109.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -82.20 M |
| Pulangan Atas Aset (ROA TTM) | -12.53% |
| Pulangan Atas Ekuiti (ROE TTM) | -23.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (GB) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | OXFORD NANOPORE TECHNOLOGIES PL | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.30 |
| RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | 1.08 |
| IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
| IOVANCE BIOTHERAPEUTICS INC IOV | 304 M | - | - | - |
| PURETECH HEALTH PLC ORD 1P | 292 M | - | 9.31 | 1.07 |
| FARON PHARMACEUTICALS OY ORD NP | 231 M | - | - | 165.73 |
|
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 42.94% |
| % Dimiliki oleh Institusi | 43.11% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |